ArticleCureus2024
Cone-Beam Computed Tomography (CBCT)-Based Online Adaptive Radiation Therapy (oART) for a Prostate Cancer Patient With Inflammatory Bowel Disease and Bilateral Total Hip Arthroplasty: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report addresses the complex management of a patient with concurrent prostate cancer, inflammatory bowel disease (IBD), and bilateral total hip arthroplasty, and demonstrates the efficacy of cone-beam computed tomography (CBCT)-guided daily online adaptive radiation therapy (oART) and advanced imaging techniques in overcoming significant treatment challenges. A 68-year-old male with a history of ulcerative colitis and bilateral hip prostheses was diagnosed with high-risk prostate cancer. Conventional radiation therapy modalities, including external beam radiation therapy (EBRT), proton therapy, and magnetic resonance imaging (MRI)-based oART, faced limitations because of the patient's comorbidities and metallic implants. Daily oART, using the Ethos platform (Varian Medical Systems, Palo Alto, CA, USA) with HyperSight™ metal artifact reduction (MAR) imaging, was employed to enhance treatment efficacy. The daily oART treatment on the Ethos platform facilitated the successful delivery of a therapeutic dose while sparing healthy tissues, and the treatment was successful without an IBD flare-up. Daily oART also optimized the target dose while best sparing the critical organs based on the patient's daily anatomy. The HyperSight MAR algorithm significantly reduced imaging artifacts caused by the hip prostheses, enabling accurate identification of the prostate, bladder, and surrounding organs. The oART workflow was delivered without technical challenges, with a total session time of 20 to 30 minutes, similar to our typical prostate patients without hip implants. Despite the complex anatomy and comorbid conditions, the treatment plan met all organ-at-risk constraints and delivered the prescribed dose to the target volumes. Ethos oART with HyperSight provided an effective solution for treating a patient with concurrent prostate cancer, IBD, and bilateral hip arthroplasty. The patient's case was successfully treated without complications, despite such challenging clinical and technical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.